JP2012505253A5 - - Google Patents

Download PDF

Info

Publication number
JP2012505253A5
JP2012505253A5 JP2011531244A JP2011531244A JP2012505253A5 JP 2012505253 A5 JP2012505253 A5 JP 2012505253A5 JP 2011531244 A JP2011531244 A JP 2011531244A JP 2011531244 A JP2011531244 A JP 2011531244A JP 2012505253 A5 JP2012505253 A5 JP 2012505253A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
patient
cyproterone acetate
agent according
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011531244A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505253A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/060381 external-priority patent/WO2010042930A1/en
Publication of JP2012505253A publication Critical patent/JP2012505253A/ja
Publication of JP2012505253A5 publication Critical patent/JP2012505253A5/ja
Pending legal-status Critical Current

Links

JP2011531244A 2008-10-10 2009-10-12 低用量酢酸シプロテロンを用いる、去勢された前立腺癌患者における血管運動症状の治療方法 Pending JP2012505253A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13689308P 2008-10-10 2008-10-10
US61/136,893 2008-10-10
PCT/US2009/060381 WO2010042930A1 (en) 2008-10-10 2009-10-12 Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate

Publications (2)

Publication Number Publication Date
JP2012505253A JP2012505253A (ja) 2012-03-01
JP2012505253A5 true JP2012505253A5 (OSRAM) 2013-06-06

Family

ID=42101000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011531244A Pending JP2012505253A (ja) 2008-10-10 2009-10-12 低用量酢酸シプロテロンを用いる、去勢された前立腺癌患者における血管運動症状の治療方法

Country Status (9)

Country Link
US (1) US8288342B2 (OSRAM)
EP (1) EP2381946A4 (OSRAM)
JP (1) JP2012505253A (OSRAM)
AU (1) AU2009303272A1 (OSRAM)
BR (1) BRPI0914024A2 (OSRAM)
CA (1) CA2739887A1 (OSRAM)
EA (1) EA022208B1 (OSRAM)
MX (1) MX2011003726A (OSRAM)
WO (1) WO2010042930A1 (OSRAM)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2345377A1 (de) * 1973-09-06 1975-03-20 Schering Ag Pharmazeutische zubereitung i
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
DE3331824A1 (de) 1983-09-01 1985-03-21 Schering AG, Berlin und Bergkamen, 1000 Berlin Verfahren zur herstellung von 17(alpha)-acyloxy-6-chlor-1(alpha),2(alpha)-methylen-3,20-dionen
DE3333240A1 (de) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4498420A (en) 1984-01-23 1985-02-12 Container Corporation Of America Carton for insects
DE3934656A1 (de) 1989-10-13 1991-04-18 Schering Ag Verfahren zur herstellung von waessrigen dispersionen
DE3936328A1 (de) 1989-10-27 1991-05-02 Schering Ag Pharmazeutische praeparate
IE67345B1 (en) 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
BE1007402A5 (nl) 1993-03-26 1995-06-06 Adir Nasale farmaceutische preparaten met progestagene stof.
US6165504A (en) * 1998-09-23 2000-12-26 Barr Laboratories, Inc. Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients
US6613758B1 (en) * 1999-04-02 2003-09-02 Barr Laboratories, Inc. Method for treating osteoporosis in castrated prostatic cancer patients
FR2821555B1 (fr) * 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
US20040024230A1 (en) 2002-04-29 2004-02-05 Boehringer Ingelheim International Gmbh Synthesis of cyproterone acetate
US20050020552A1 (en) 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US7371405B2 (en) 2003-12-22 2008-05-13 Mcneil-Ppc, Inc. Consumer customized dosage forms
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs

Similar Documents

Publication Publication Date Title
JP5973411B2 (ja) 医薬組成物
RU2314810C2 (ru) Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена
JP2013511507A5 (OSRAM)
RS55206B1 (sr) Kompozicije za lečenje centralno posredovane mučnine i povraćanja
RU2011138490A (ru) Фармацевтические композиции с мгновенным высвобождением, содержащие оксикодон и налоксон
JP2018507243A5 (OSRAM)
AU2014216373B2 (en) Pharmaceutical compositions for the treatment of Helicobacter pylori
JP2011503063A5 (OSRAM)
CN1531420A (zh) 用于有效施用阿扑吗啡、6аR-(-)-N-丙基-去甲阿扑吗啡和它们的衍生物及其前药的药物制剂
CN1481241A (zh) 阿洛地平和贝那普利/苯那普利拉的治疗组合
KR101156054B1 (ko) 안정한 에페리손 함유 서방성 의약조성물
JP2017132791A (ja) 組み合わせ組成物
AU2014299447B2 (en) Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
BR112019027286A2 (pt) formulação de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva
JP2009517411A5 (OSRAM)
JP2006511538A (ja) 非ヌクレオシド系逆転写酵素阻害剤(nnrti)とプロテアーゼ阻害剤などのシトクロムp450の阻害剤とを含む組み合わせの使用
RU2261098C2 (ru) Перорально распадающаяся композиция, содержащая миртазапин
JP2004525940A (ja) 火照りの処置のためのデュロキセチン
CA3222959A1 (en) Naltrexone for boosting the therapeutic utility of 5-ht receptor agonists
ES2652266T3 (es) Composición sólida de dosificación oral de ibuprofeno que comprende un copolímero de ácido metacrílico
CN104936585B (zh) 包括苯肾上腺素和扑热息痛的组合药剂
JP2012505253A5 (OSRAM)
TW201105329A (en) Medicament for the long term NSAID use
CA2612179A1 (en) A pharmaceutical composition comprising loratadine and its use to treat patients with upper respiratory mucosal congestion
CN116157127A (zh) 化合物用于治疗口干燥症的用途